Literature DB >> 11533188

Function of Rta is essential for lytic replication of murine gammaherpesvirus 68.

T T Wu1, L Tong, T Rickabaugh, S Speck, R Sun.   

Abstract

Rta, encoded primarily by open reading frame 50, is well conserved among gammaherpesviruses. It has been shown that the Rta proteins of Epstein Barr virus (EBV), Kaposi's sarcoma-associated herpesvirus (KSHV, or HHV-8), and murine gammaherpesvirus 68 (MHV-68; also referred to as gamma HV68) play an important role in viral reactivation from latency. However, the role of Rta during productive de novo infection has not been characterized in gammaherpesviruses. Since there are cell lines that can support efficient productive de novo infection by MHV-68 but not EBV or KSHV, we examined whether MHV-68 Rta plays a role in initiating viral lytic replication in productively infected cells. Rta, functioning as a transcriptional activator, can activate the viral promoter of early lytic genes. The amino acid sequence alignments of the Rta homologues suggest that the organizations of their functional domains are similar, with the DNA binding and dimerization domains at the N terminus and the trans-activation domain at the C terminus. We constructed two mutants of MHV-68 Rta, Rd1 and Rd2, with deletions of 112 and 243 amino acids from the C terminus, respectively. Rd1 and Rd2 could no longer trans-activate the promoter of MHV-68 gene 57, consistent with the deletions of their trans-activation domains at the C terminus. Furthermore, Rd1 and Rd2 were able to function as dominant-negative mutants, inhibiting trans-activation of wild-type Rta. To study whether Rd1 and Rd2 blocked viral lytic replication, purified virion DNA was cotransfected with Rd1 or Rd2 into fibroblasts. Expression of viral lytic proteins was greatly suppressed, and the yield of infectious viruses was reduced up to 10(4)-fold. Stable cell lines constitutively expressing Rd2 were established and infected with MHV-68. Transcription of the immediate-early gene, rta, and the early gene, tk, of the virus was reduced in these cell lines. The presence of Rd2 also led to attenuation of viral lytic protein expression and virion production. The ability of Rta dominant-negative mutants to inhibit productive infection suggests that the trans-activation function of Rta is essential for MHV-68 lytic replication. We propose that a single viral protein, Rta, governs the initiation of MHV-68 lytic replication during both reactivation and productive de novo infection.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11533188      PMCID: PMC114493          DOI: 10.1128/JVI.75.19.9262-9273.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  25 in total

1.  The Epstein-Barr virus BMLF1 promoter contains an enhancer element that is responsive to the BZLF1 and BRLF1 transactivators.

Authors:  S Kenney; E Holley-Guthrie; E C Mar; M Smith
Journal:  J Virol       Date:  1989-09       Impact factor: 5.103

2.  The Epstein-Barr virus (EBV) early protein EB2 is a posttranscriptional activator expressed under the control of EBV transcription factors EB1 and R.

Authors:  M Buisson; E Manet; M C Trescol-Biemont; H Gruffat; B Durand; A Sergeant
Journal:  J Virol       Date:  1989-12       Impact factor: 5.103

3.  Activation of expression of latent Epstein-Barr herpesvirus after gene transfer with a small cloned subfragment of heterogeneous viral DNA.

Authors:  J Countryman; G Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1985-06       Impact factor: 11.205

4.  Characterization of gammaherpesvirus 68 gene 50 transcription.

Authors:  S Liu; I V Pavlova; H W Virgin; S H Speck
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

5.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

Authors:  P Chomczynski; N Sacchi
Journal:  Anal Biochem       Date:  1987-04       Impact factor: 3.365

6.  Kaposi's sarcoma-associated herpesvirus open reading frame 50/Rta protein activates the entire viral lytic cycle in the HH-B2 primary effusion lymphoma cell line.

Authors:  L Gradoville; J Gerlach; E Grogan; D Shedd; S Nikiforow; C Metroka; G Miller
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

7.  Auto-activation of the rta gene of human herpesvirus-8/Kaposi's sarcoma-associated herpesvirus.

Authors:  Hongyu Deng; Arthur Young; Ren Sun
Journal:  J Gen Virol       Date:  2000-12       Impact factor: 3.891

8.  Transcriptional activation by the product of open reading frame 50 of Kaposi's sarcoma-associated herpesvirus is required for lytic viral reactivation in B cells.

Authors:  D M Lukac; J R Kirshner; D Ganem
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

9.  Both Epstein-Barr virus (EBV)-encoded trans-acting factors, EB1 and EB2, are required to activate transcription from an EBV early promoter.

Authors:  A Chevallier-Greco; E Manet; P Chavrier; C Mosnier; J Daillie; A Sergeant
Journal:  EMBO J       Date:  1986-12-01       Impact factor: 11.598

10.  Epstein-Barr virus bicistronic mRNAs generated by facultative splicing code for two transcriptional trans-activators.

Authors:  E Manet; H Gruffat; M C Trescol-Biemont; N Moreno; P Chambard; J F Giot; A Sergeant
Journal:  EMBO J       Date:  1989-06       Impact factor: 11.598

View more
  57 in total

1.  Inhibition of gammaherpesvirus replication by RNA interference.

Authors:  Qingmei Jia; Ren Sun
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

2.  Disruption of gammaherpesvirus 68 gene 50 demonstrates that Rta is essential for virus replication.

Authors:  Iglika V Pavlova; Herbert W Virgin; Samuel H Speck
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

3.  Poly(ADP-ribose) polymerase 1 and Ste20-like kinase hKFC act as transcriptional repressors for gamma-2 herpesvirus lytic replication.

Authors:  Yousang Gwack; Hiroyuki Nakamura; Sun Hwa Lee; John Souvlis; Jason T Yustein; Steve Gygi; Hsing-Jien Kung; Jae U Jung
Journal:  Mol Cell Biol       Date:  2003-11       Impact factor: 4.272

4.  Generation of a latency-deficient gammaherpesvirus that is protective against secondary infection.

Authors:  Tammy M Rickabaugh; Helen J Brown; DeeAnn Martinez-Guzman; Ting-Ting Wu; Leming Tong; Fuqu Yu; Steven Cole; Ren Sun
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

5.  The herpesvirus saimiri open reading frame (ORF) 50 (Rta) protein contains an at hook required for binding to the ORF 50 response element in delayed-early promoters.

Authors:  Matthew S Walters; Kersten T Hall; Adrian Whitehouse
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

6.  COX-2 induction during murine gammaherpesvirus 68 infection leads to enhancement of viral gene expression.

Authors:  Tonia L Symensma; DeeAnn Martinez-Guzman; Qingmei Jia; Eric Bortz; Ting-Ting Wu; Nandini Rudra-Ganguly; Steve Cole; Harvey Herschman; Ren Sun
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

7.  Gammaherpesvirus gene expression and DNA synthesis are facilitated by viral protein kinase and histone variant H2AX.

Authors:  Bryan C Mounce; Fei Chin Tsan; Lindsay Droit; Sarah Kohler; Justin M Reitsma; Lisa A Cirillo; Vera L Tarakanova
Journal:  Virology       Date:  2011-09-22       Impact factor: 3.616

8.  Transcription program of murine gammaherpesvirus 68.

Authors:  DeeAnn Martinez-Guzman; Tammy Rickabaugh; Ting-Ting Wu; Helen Brown; Steven Cole; Moon Jung Song; Leming Tong; Ren Sun
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

9.  Murine Gammaherpesvirus 68 ORF48 Is an RTA-Responsive Gene Product and Functions in both Viral Lytic Replication and Latency during In Vivo Infection.

Authors:  Jing Qi; Chuanhui Han; Danyang Gong; Ping Liu; Sheng Zhou; Hongyu Deng
Journal:  J Virol       Date:  2015-03-11       Impact factor: 5.103

10.  Identification of an Rta responsive promoter involved in driving gammaHV68 v-cyclin expression during virus replication.

Authors:  Robert D Allen; Mark N DeZalia; Samuel H Speck
Journal:  Virology       Date:  2007-05-02       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.